Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

At last, a weight neutral insulin?

A Fritsche1, H Häring

  • 1Internal Medicine Department IV, Eberhard Karls University Hospital, Tübingen, Germany. andreas.fritsche@med.uni-tuebingen.de

International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity
|August 13, 2004
PubMed
Summary

Weight gain is a concern in diabetes treatment. New insulin detemir shows significantly less weight gain compared to NPH insulin, offering better glycaemic control without weight increase.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glucagon-like peptide 1 (GLP-1).

Molecular metabolism·2019
Same author

Fetal auditory evoked responses to onset of amplitude modulated sounds. A fetal magnetoencephalography (fMEG) study.

Hearing research·2018
Same author

The protective effect of human renal sinus fat on glomerular cells is reversed by the hepatokine fetuin-A.

Scientific reports·2017
Same author

An extended fatty liver index to predict non-alcoholic fatty liver disease.

Diabetes & metabolism·2017
Same author

Gestational diabetes alters the fetal heart rate variability during an oral glucose tolerance test: a fetal magnetocardiography study.

BJOG : an international journal of obstetrics and gynaecology·2016
Same author

Association between omentin-1, adiponectin and bone health under consideration of osteoprotegerin as possible mediator.

Journal of endocrinological investigation·2016

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Weight gain is a known side effect of diabetes medications, including insulin and oral antidiabetic drugs.
  • This weight increase can negatively impact glycaemic control, beta-cell function, hypertension, and lipid levels in both type 1 and type 2 diabetes.
  • Fear of weight gain can be a significant barrier to initiating or intensifying insulin therapy, potentially leading to delayed treatment or under-dosing.

Purpose of the Study:

  • To evaluate the weight gain profile of insulin detemir compared to NPH insulin in patients with diabetes.
  • To explore the potential for improved glycaemic control without adverse weight changes in diabetes management.

Main Methods:

  • Utilized studies involving insulin detemir, a long-acting soluble insulin analogue with consistent absorption due to albumin binding.

Related Experiment Videos

  • Compared weight changes in patients using insulin detemir in basal-bolus regimens versus those using NPH insulin.
  • Investigated the pharmacokinetic properties of insulin detemir, including its reversible binding to albumin for protraction.

    • Main Results:

    • Studies demonstrated significantly less weight gain with insulin detemir compared to NPH insulin in both type 1 and type 2 diabetes patients.
    • Insulin detemir exhibits consistent absorption and low injection-to-injection variability.
    • The data suggest that weight gain associated with insulin therapy is not an inevitable outcome.

    Conclusions:

    • Insulin detemir offers a potential advantage in diabetes management by allowing for improved glycaemic control while maintaining weight stability.
    • This can lead to both immediate and long-term benefits for patients, addressing a key barrier to effective insulin therapy.
    • Further research is ongoing to elucidate the precise mechanisms behind these observed outcomes.